OXER1; FFAR1; FFAR4; ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA2A; DRD4; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
RECQL; TDP1; PLA2G1B; CDA; ALPI; FAAH; CTDSP1; TERT; ADK; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; NOX4; PYGL; APEX1; POLB; | |
PTPN1; | |
ACHE; GAA; | |
TRPA1; | |
AKT1; MET; CAMK2B; CSNK2A1; DAPK1; AXL; FLT3; NEK6; NEK2; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; KDR; PKN1; | |
CA14; CA5B; CA3; CA7; CA5A; CA9; CA4; CA6; CA2; CA12; CA1; | |
PPARA; PPARG; PPARD; | |
AR; | |
NR1I2; | |
RXRA; | |
ESRRA; | |
ESR2; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; TYR; XDH; | |
CASP7; CASP1; | |
MMP13; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
SLC28A2; SLC28A1; SLC28A3; | |
ABCC1; ABCG2; | |
LMNA; FABP4; MAPT; FABP3; FABP5; HTT; SAE1; FABP2; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Small molecule receptor (family A GPCR) | OXER1 | Oxoeicosanoid receptor 1 | Q8TDS5 | CHEMBL1628461 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | SAE1 | SUMO-activating enzyme subunit 1 | Q9UBE0 | CHEMBL1615388 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.512E-13 | 1.497E-10 | ALPI, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CDA, ESR2, ESRRA, GLO1, MMP1, MMP13, MMP2, MMP3, MMP9, NR1I2, PPARA, PPARD, PPARG, PTPN1, RXRA, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.083E-11 | 3.802E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.338E-11 | 4.624E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.456E-11 | 7.640E-09 | AHR, AR, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG, RXRA |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.970E-11 | 1.153E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, SRC |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.825E-11 | 1.647E-08 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.415E-10 | 1.102E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.671E-09 | 2.931E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.262E-09 | 5.300E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 4.127E-09 | 6.511E-07 | AR, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG, RXRA |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.004E-09 | 9.142E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.482E-08 | 3.179E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.197E-08 | 5.253E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
MF | Unclassified; | GO:0004872; receptor activity | 4.196E-08 | 5.253E-06 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESR2, ESRRA, FFAR1, FFAR4, FLT3, HPGD, IGF1R, KDR, MET, NMUR2, NPSR1, NR1I2, OXER1, PPARA, PPARD, PPARG, RXRA, TLR2, TSHR |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.372E-07 | 1.548E-05 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AHR, AXL, HIF1A, NFKB1, PIK3R1, PPARD, PPARG, RXRA, SAE1, TLR2, TP53, TYR |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.697E-07 | 1.876E-05 | AR, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG, RXRA, SRC |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 4.445E-07 | 4.474E-05 | ADORA1, ADORA2A, ADRA2A, AURKB, CA2, CA7, HIF1A, HTT, KDR, MAPK1, NEK2, NPSR1, PLA2G1B, SRC, TRPA1 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 6.585E-07 | 6.234E-05 | ADK, AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, CAMK2B, CASP7, CDK1, CSNK2A1, CTDSP1, ESR2, ESRRA, FABP5, GSK3B, HIF1A, HPGD, HTT, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1I2, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, RXRA, SAE1, SMN1, SMN2, SRC, STAT6, TERT, TP53 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 6.755E-07 | 6.326E-05 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 7.244E-07 | 6.717E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.947E-07 | 7.333E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 8.139E-07 | 7.446E-05 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 9.869E-07 | 8.880E-05 | AR, CDK1, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG, RXRA |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.021E-06 | 9.112E-05 | ADORA1, ADORA2A, CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, SRC, TRPA1 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.276E-06 | 1.081E-04 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.424E-06 | 1.175E-04 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.833E-06 | 1.479E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.162E-06 | 1.712E-04 | ADORA2A, AURKB, CA2, CA7, HIF1A, HTT, MAPK1, NEK2, NPSR1, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.621E-06 | 2.038E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.702E-06 | 2.086E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.864E-06 | 2.204E-04 | ALOX12, ALOX15, ALOX5, HPGD |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.007E-06 | 2.289E-04 | AKT1, APEX1, AR, CASP7, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, PPARG, SRC |
BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 3.591E-06 | 2.624E-04 | ADORA2A, AKT1, CASP1, KDR, MAPT, SRC |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 4.754E-06 | 3.394E-04 | AKT1, AR, DAPK1, HTT, LMNA, SRC, TERT |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.070E-06 | 3.573E-04 | AKT1, HIF1A, LMNA, PPARD, SRC, TERT, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.217E-06 | 3.664E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 5.754E-06 | 4.003E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 7.355E-06 | 4.974E-04 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 7.775E-06 | 5.225E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 9.086E-06 | 5.977E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 9.185E-06 | 5.985E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 9.198E-06 | 5.985E-04 | ADRA2A, AKT1, FFAR1, HIF1A, NOX4, PIK3R1, PPARG, PYGL |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.117E-05 | 7.112E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.323E-05 | 8.373E-04 | AKT1, FABP3, FFAR1, PPARG, SRC, TLR2 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.447E-05 | 8.951E-04 | ADRA2A, ADRA2C, DRD4 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.903E-05 | 1.148E-03 | FABP2, FABP3, FABP4, FABP5 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.005E-05 | 1.193E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 2.160E-05 | 1.271E-03 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 2.194E-05 | 1.281E-03 | AKT1, CDK1, MAPK1, PIK3R1, SRC, TERT, TLR2 |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 2.253E-05 | 1.308E-03 | ACHE, ADORA2A, CASP1, FFAR1, HIF1A, PLA2G1B, PPARD, SRC, TLR2 |
BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 2.490E-05 | 1.427E-03 | ADORA1, ADORA2A, ADRA2A, AKT1, DRD4, FFAR1, HTT, NPSR1, PLA2G1B |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.864E-05 | 1.613E-03 | ABCC1, ADORA1, ADRA2A, CA2, CA4, CA9, HPGD, TSHR |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 3.034E-05 | 1.694E-03 | AKT1, FABP3, PPARA, PPARG |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.034E-05 | 1.694E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 3.071E-05 | 1.706E-03 | PPARG, SRC, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 3.071E-05 | 1.706E-03 | ABCC1, ABCG2, NR1I2 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 3.264E-05 | 1.795E-03 | ABCC1, ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, BACE1, DRD4, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, SLC28A1, SLC28A2, SLC28A3, TLR2, TRPA1, TSHR |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 4.051E-05 | 2.200E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1 |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 4.155E-05 | 2.206E-03 | SLC28A2, SLC28A3 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.155E-05 | 2.206E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.155E-05 | 2.206E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 4.155E-05 | 2.206E-03 | CDA, MAPK1 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 4.155E-05 | 2.206E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.155E-05 | 2.206E-03 | ALOX12, ALOX15 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 4.155E-05 | 2.206E-03 | SLC28A2, SLC28A3 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 4.203E-05 | 2.221E-03 | GSK3B, HTT, MAPT |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 4.214E-05 | 2.222E-03 | ADORA1, ADORA2A, DRD4, PPARA, PPARG, TP53 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.593E-05 | 2.370E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 4.566E-05 | 2.370E-03 | ADK, AHR, AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AR, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDA, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, HTT, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PYGL, SMN1, SMN2, SRC, STAT6, TP53, TYR, XDH |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 5.046E-05 | 2.567E-03 | ADORA1, ADORA2A, ADORA3, AR, CYP1B1, FABP3, LMNA, NOX4, PKN1, PPARD, PPARG, TERT, TLR2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 5.246E-05 | 2.656E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, HTT, KDR, PPARA, PTK2, PTPN1 |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 5.308E-05 | 2.675E-03 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, HPGD, IGF1R, KDR, MET, NMUR2, NPSR1, OXER1, PPARG, TSHR |
MF | GO:0005488; binding | GO:0042277; peptide binding | 6.271E-05 | 3.104E-03 | ACHE, BACE1, FFAR4, IGF1R, NMUR2, PIK3R1, PPARG, RXRA, TLR2 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 6.341E-05 | 3.131E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 6.669E-05 | 3.271E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 7.216E-05 | 3.484E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 7.216E-05 | 3.484E-03 | ADORA2A, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 7.879E-05 | 3.775E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
MF | GO:0005488; binding | GO:0002039; p53 binding | 9.054E-05 | 4.249E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 9.769E-05 | 4.555E-03 | AHR, AXL, CSNK2A1, DRD4, GSK3B, PPARA, PPARG, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.036E-04 | 4.779E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.040E-04 | 4.780E-03 | MMP2, MMP9, PPARD, RXRA |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.040E-04 | 4.780E-03 | AKT1, CASP1, CASP7, PTK2 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.079E-04 | 4.938E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB, TYR |
BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 1.128E-04 | 5.086E-03 | ADORA2A, ADRA2A, CAMK2B, DRD4, FFAR1, HTT, NPSR1, PLA2G1B |
BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 1.163E-04 | 5.210E-03 | GSK3B, HIF1A, HTT, KDR, MMP9, SAE1, TP53 |
BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 1.181E-04 | 5.268E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 1.181E-04 | 5.268E-03 | CDA, HSD17B10, RXRA, TP53, TRPA1 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.241E-04 | 5.405E-03 | SLC28A1, SLC28A3 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.241E-04 | 5.405E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.241E-04 | 5.405E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.241E-04 | 5.405E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.241E-04 | 5.405E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.241E-04 | 5.405E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.241E-04 | 5.405E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0050692; DBD domain binding | 1.241E-04 | 5.405E-03 | PPARG, RXRA |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.241E-04 | 5.405E-03 | ADORA1, ADORA2A |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.340E-04 | 5.752E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 1.352E-04 | 5.771E-03 | CDA, ESR2, HIF1A, MPO, PPARD, PPARG, PTK2, TP53 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 1.393E-04 | 5.903E-03 | ADORA1, ADORA2A, MAPT |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.559E-04 | 6.518E-03 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AKT1, PPARD |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.610E-04 | 6.715E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0032501; multicellular organismal process | GO:0010634; positive regulation of epithelial cell migration | 1.630E-04 | 6.781E-03 | AKT1, HIF1A, KDR, MET, MMP9, SRC |
BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 1.684E-04 | 6.917E-03 | AKT1, CYP1B1, TLR2 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.684E-04 | 6.917E-03 | AURKB, MAPK1, NEK2 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.684E-04 | 6.917E-03 | CYP1A1, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.684E-04 | 6.917E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.684E-04 | 6.917E-03 | AURKB, CDK1, PKN1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.811E-04 | 7.331E-03 | AKR1B1, AKT1, AR, PPARG, SRC |
BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 1.856E-04 | 7.470E-03 | AKT1, ALK, AR, ESR2, NFKB1, PLA2G1B, PPARG, TLR2 |
BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.919E-04 | 7.667E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.938E-04 | 7.701E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, CAMK2B, CDA, FLT3, HPGD, MAPT, NFKB1, PYGL, TERT, TYR, XDH |
MF | Unclassified; | GO:0032403; protein complex binding | 1.938E-04 | 7.701E-03 | ACHE, ADORA1, ADRA2A, APEX1, FLT3, IGF1R, KDR, MMP13, MMP9, PIK3R1, PPARA, PTPN1, SRC, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.011E-04 | 7.946E-03 | AKT1, HIF1A, TERT |
BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 2.011E-04 | 7.946E-03 | ADORA2A, PPARG, TP53 |
BP | GO:0007610; behavior | GO:0007610; behavior | 2.022E-04 | 7.956E-03 | ADORA2A, ALK, DRD4, GAA, HIF1A, HTT, MAPK1, MAPT, NMUR2, PPARA, TLR2, TP53 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 2.028E-04 | 7.956E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0009987; cellular process | GO:1901215; negative regulation of neuron death | 2.102E-04 | 8.195E-03 | ADORA2A, AKT1, AXL, GSK3B, HIF1A, PPARA, TERT |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.188E-04 | 8.479E-03 | ADRA2C, AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, ESRRA, GSK3B, HIF1A, KDR, MAPT, PIK3R1, PIM1, PPARD, PPARG, PTK2, RXRA, SRC, STAT6, TERT, TLR2, XDH |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.404E-04 | 9.150E-03 | IGF1R, KDR, PTK2, SRC |
BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 2.404E-04 | 9.150E-03 | AKT1, NFKB1, PPARA, PPARG |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.399E-04 | 9.150E-03 | AR, CYP3A4, ESR2, ESRRA, HSD17B1 |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 2.472E-04 | 9.279E-03 | NMUR2, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.472E-04 | 9.279E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.472E-04 | 9.279E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.472E-04 | 9.279E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0032795; heterotrimeric G-protein binding | 2.472E-04 | 9.279E-03 | ADORA1, ADRA2A |
MF | GO:0005488; binding | GO:0005497; androgen binding | 2.472E-04 | 9.279E-03 | ALDH1A1, AR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.099E-22 | 7.729E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.408E-15 | 3.710E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.969E-14 | 1.649E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.346E-21 | 8.388E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.844E-12 | 5.639E-10 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; RXRA; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.581E-11 | 2.304E-09 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 4.494E-10 | 1.735E-08 | FABP2; FABP3; RXRA; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.733E-09 | 1.305E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.378E-10 | 1.735E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.423E-09 | 4.578E-08 | RXRA; HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.985E-08 | 6.991E-07 | CDA; PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; FUT7; HSD17B1; ALOX5; HSD17B2; XDH; GAA; TYR; CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; ALPI |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.926E-09 | 1.430E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.513E-08 | 5.390E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.479E-08 | 6.715E-07 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.416E-08 | 1.032E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.590E-08 | 1.184E-06 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.256E-07 | 2.721E-06 | GSK3B; PIK3R1; PTK2; NFKB1; IGF1R; RXRA; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.424E-07 | 3.671E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.004E-07 | 2.579E-06 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.308E-07 | 3.671E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; ESR2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.259E-08 | 1.078E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.651E-07 | 7.772E-06 | GSK3B; RXRA; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.698E-07 | 7.994E-06 | ABCC1; ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.215E-06 | 1.065E-05 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.895E-06 | 1.463E-05 | GSK3B; RXRA; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.109E-07 | 7.825E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.328E-06 | 1.068E-05 | ALK; RXRA; AKT1; MAPK1; PIK3R1; TP53 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.909E-06 | 2.079E-05 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; ESR2 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.328E-06 | 1.068E-05 | FABP4; ADORA1; AKT1; PIK3R1; TSHR; PTGS1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.511E-06 | 2.768E-05 | CAMK2B; ADORA2A; ADORA1; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.214E-06 | 1.644E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 5.095E-06 | 2.980E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.792E-06 | 2.440E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.228E-06 | 2.148E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.874E-06 | 3.149E-05 | CASP7; MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.529E-06 | 3.049E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.228E-06 | 2.148E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.043E-05 | 5.297E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.428E-06 | 3.049E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.329E-05 | 1.083E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.590E-06 | 2.768E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.841E-05 | 1.246E-04 | CASP7; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.356E-05 | 1.083E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.914E-06 | 3.607E-05 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.123E-05 | 1.730E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.651E-05 | 8.170E-05 | RXRA; AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.610E-05 | 1.853E-04 | GSK3B; CASP7; RXRA; AKT1; PIK3R1; PPARA; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 5.497E-05 | 2.165E-04 | ADORA2A; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.745E-05 | 1.232E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 9.166E-05 | 3.243E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 8.711E-05 | 3.233E-04 | ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.819E-04 | 9.069E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.083E-04 | 9.754E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.808E-05 | 8.723E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.834E-05 | 3.330E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.558E-04 | 1.108E-03 | ADORA2A; ADORA3; ADORA1; NMUR2; ADRA2C; ADRA2A; DRD4; TSHR |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.409E-04 | 7.881E-04 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.282E-05 | 1.758E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.410E-05 | 3.243E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.410E-05 | 3.243E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.644E-04 | 1.534E-03 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.797E-05 | 2.194E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.797E-05 | 2.194E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.757E-04 | 1.133E-03 | CAMK2B; TRPA1; SRC; ALOX12; PIK3R1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.757E-04 | 1.133E-03 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 8.181E-04 | 2.134E-03 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.610E-04 | 1.758E-03 | BACE1; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.939E-04 | 1.402E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 5.389E-04 | 1.492E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.939E-04 | 1.402E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 6.648E-04 | 1.758E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 8.937E-04 | 2.269E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 9.410E-05 | 3.243E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.201E-03 | 2.861E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.018E-03 | 2.498E-03 | SRC; AKT1; MAPK1; PIK3R1; PTGS1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.056E-03 | 2.548E-03 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.994E-03 | 4.423E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.446E-03 | 3.296E-03 | AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.306E-03 | 3.037E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.994E-03 | 4.423E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 6.158E-03 | 1.238E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.739E-02 | 3.023E-02 | PIM1; AKT1; STAT6; PIK3R1 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.344E-02 | 3.834E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.400E-02 | 2.501E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 7.666E-03 | 1.494E-02 | AKT1; PPARG; PIK3R1; IGF1R |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.277E-02 | 2.303E-02 | CXCR1; AKT1; MAPK1; PIK3R1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 3.592E-03 | 7.535E-03 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.210E-02 | 3.645E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.739E-02 | 3.023E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 3.592E-03 | 7.535E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 6.452E-03 | 1.284E-02 | MMP2; PIK3R1; MMP9; PTK2 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.722E-03 | 7.643E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 9.754E-03 | 1.793E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.722E-03 | 7.643E-03 | CAMK2B; AKT1; PYGL; PPARA |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.556E-03 | 5.542E-03 | CAMK2B; SRC; MMP2; MAPK1 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 8.325E-03 | 1.575E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.410E-04 | 1.492E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 9.696E-04 | 2.430E-03 | RXRA; AKT1; PPARA; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.080E-03 | 4.561E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.057E-02 | 3.423E-02 | AKT1; MAPK1; PIK3R1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.452E-03 | 3.296E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 8.695E-04 | 2.237E-03 | CXCR1; SRC; MET; NFKB1 |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 1.888E-02 | 3.196E-02 | MMP1; MMP3; TLR2 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.255E-03 | 2.953E-03 | CASP7; CASP1; MAPK1; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.023E-03 | 2.498E-03 | RXRA; CA2; CYP3A4; ABCG2 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.779E-02 | 3.066E-02 | SRC; CDK1; MAPK1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.876E-04 | 1.133E-03 | CASP7; CASP1; NFKB1; TLR2 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.079E-02 | 1.964E-02 | MAPK1; NFKB1; TLR2 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 8.889E-03 | 1.666E-02 | AKT1; MAPK1; PIK3R1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 7.524E-03 | 1.482E-02 | AKT1; PIK3R1; IGF1R |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.060E-05 | 1.312E-04 | RXRA; MAPK1; PPARG; TP53 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.853E-03 | 1.501E-02 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 7.853E-03 | 1.501E-02 | STAT6; NFKB1; TLR2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 5.454E-03 | 1.108E-02 | CASP1; MAPK1; NFKB1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.116E-04 | 3.715E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.090E-02 | 4.929E-02 | ABCC1; ABCG2 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.974E-03 | 6.377E-03 | CDA; CYP3A4; XDH |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.470E-02 | 4.006E-02 | MAPK1; PIK3R1 |
hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.711E-02 | 4.360E-02 | FABP2; PLA2G1B |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.504E-02 | 2.662E-02 | GAA; AKR1B1 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.015E-02 | 3.383E-02 | MAOA; TYR |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.803E-02 | 3.080E-02 | POLB; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.997E-03 | 1.670E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.828E-04 | 1.133E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; TLR2; KDR |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
NA: NA | HIV infections | NA | AHR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; CA9; AKT1; MET; CSNK2A1; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TLR2; TP53; CA1; KDR |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; ADORA2A |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; PTGS1; FAAH |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADORA2A; ADORA1; ADRA2C; CA1; CA1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | KDR |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; NFKB1; PPARG; PPARG; PPARD |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; CDA; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TLR2; TP53; KDR; KDR; KDR |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; ADORA2A; ADORA1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | TERT; TLR2; TYR; KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1 |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; PPARG; PPARD; PPARD |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1; ADK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1 |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; PPARD |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; MMP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; ADORA2A; ADORA1; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; ADK; ACHE; PTGS1; IGF1R; ADORA2A; CDK1; ADRA2C; ADRA2A; TRPA1; FAAH |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; CASP1; MMP3; TYR; MMP1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; FAAH; CYP3A4 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C; PPARG; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADORA2A; ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TERT; FLT3; TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
NA: NA | Edema | NA | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; FFAR1; GSK3B; ADORA1; PPARG |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CA9; TERT; FLT3; FLT3; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |